{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:31:03Z","timestamp":1794022263920,"version":"4.8.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T00:00:00Z","timestamp":1576022400000},"content-version":"vor","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jacc.2018.09.057","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T16:42:08Z","timestamp":1543855328000},"page":"2915-2931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":353,"special_numbering":"PA","title":["ACC\/AHA Versus ESC Guidelines on Dual\u00a0Antiplatelet Therapy"],"prefix":"10.1016","volume":"72","author":[{"given":"Davide","family":"Capodanno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Alfonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn N.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2018.09.057_bib1","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2165\/11640880-000000000-00000","article-title":"The evolution of antiplatelet therapy in the treatment of acute coronary syndromes","volume":"72","author":"Angiolillo","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.jacc.2018.09.057_bib2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","article-title":"Novel antiplatelet agents in acute coronary syndrome","volume":"12","author":"Franchi","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrcardio.2017.18","article-title":"Antithrombotic therapy for patients with STEMI undergoing primary PCI","volume":"14","author":"Franchi","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib4","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.pcad.2017.12.004","article-title":"Evolution of coronary stent technology and implications for duration of dual antiplatelet therapy","volume":"60","author":"Moon","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2018.09.057_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17474086.2018.1400378","article-title":"The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts","volume":"11","author":"Moon","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jacc.2018.09.057_bib6","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.057_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehy658","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","author":"Neumann","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.057_bib9","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"[DAPT] twelve or 30\u00a0months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.057_bib10","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.09.057_bib11","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.057_bib12","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.057_bib13","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.057_bib14","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1016\/j.jacc.2014.09.016","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib15","first-page":"485","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O\u2019Gara","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib16","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.057_bib17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.057_bib18","doi-asserted-by":"crossref","first-page":"e002301","DOI":"10.1161\/CIRCINTERVENTIONS.114.002301","article-title":"Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines","volume":"8","author":"Capodanno","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2018.09.057_bib19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.057_bib20","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.057_bib21","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","article-title":"A\u00a0Randomized Trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents","volume":"59","author":"Trenk","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib22","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.09.057_bib23","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.057_bib25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/clpt.2011.127","article-title":"Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects","volume":"90","author":"Simon","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2018.09.057_bib26","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.057_bib27","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y12 receptor\u2013inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.057_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrcardio.2015.113","article-title":"Switching P2Y12-receptor inhibitors in patients with coronary artery disease","volume":"13","author":"Rollini","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.2010.219","article-title":"Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies","volume":"89","author":"Angiolillo","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2018.09.057_bib31","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.057_bib32","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1016\/j.jacc.2011.08.006","volume":"58","author":"Levine","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib33","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A\u00a0new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib34","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.09.057_bib35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.057_bib36","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy","volume":"64","author":"Colombo","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib37","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12\u00a0months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Sch\u00fcpke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.057_bib38","doi-asserted-by":"crossref","first-page":"e003145","DOI":"10.1161\/CIRCINTERVENTIONS.115.003145","article-title":"Six versus 12\u00a0months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 Trial","volume":"9","author":"Han","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2018.09.057_bib39","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jcin.2016.04.036","article-title":"6-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation","volume":"9","author":"Hong","year":"2016","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2018.09.057_bib40","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.4244\/EIJ-D-17-00792","article-title":"Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy","volume":"13","author":"Lee","year":"2018","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jacc.2018.09.057_bib41","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jcin.2017.04.019","article-title":"Dual antiplatelet therapy for 6 versus 18\u00a0months after biodegradable polymer drug-eluting stent implantation","volume":"10","author":"Nakamura","year":"2017","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2018.09.057_bib42","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.057_bib43","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jcin.2017.03.049","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin","volume":"10","author":"Didier","year":"2017","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2018.09.057_bib44","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial","volume":"384","author":"Collet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.057_bib45","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.057_bib46","first-page":"365","article-title":"Stopping or continuing clopidogrel 12\u00a0months after drug-eluting stent placement: the OPTIDUAL randomized trial","volume":"37","author":"Helft","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.057_bib47","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jacc.2016.03.512","volume":"68","author":"Bittl","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib48","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","article-title":"Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials","volume":"385","author":"Palmerini","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.057_bib49","doi-asserted-by":"crossref","first-page":"h1618","DOI":"10.1136\/bmj.h1618","article-title":"Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials","volume":"350","author":"Navarese","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2018.09.057_bib50","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation","volume":"65","author":"Giustino","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib51","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/eurheartj\/ehx127","article-title":"Optimizing dual antiplatelet therapy duration after myocardial infarction: evidence-based, precision, or personalized medicine?","volume":"38","author":"Alfonso","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.057_bib52","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.057_bib53","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.057_bib54","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.jacc.2011.08.009","volume":"58","author":"Hillis","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib55","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.057_bib56","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.057_bib57","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.057_bib58","doi-asserted-by":"crossref","first-page":"e004395","DOI":"10.1161\/CIRCINTERVENTIONS.116.004395","article-title":"Antithrombotic Therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a North American perspective\u20142016 update","volume":"9","author":"Angiolillo","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2018.09.057_bib59","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective\u20142018 update","volume":"138","author":"Angiolillo","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.057_bib60","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.057_bib61","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation","volume":"65","author":"Fiedler","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib62","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.057_bib63","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.057_bib64","author":"Lip","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2018.09.057_bib65","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.057_bib66","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/2040620717733691","article-title":"The role of oral anticoagulant therapy in patients with acute coronary syndrome","volume":"8","author":"Moon","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jacc.2018.09.057_bib67","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11886-016-0749-2","article-title":"The ADAPTABLE trial and aspirin dosing in secondary prevention for patients with coronary artery disease","volume":"18","author":"Johnston","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacc.2018.09.057_bib68","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.116.023164","article-title":"Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus","volume":"134","author":"Capodanno","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.057_bib69","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCINTERVENTIONS.110.960187","article-title":"Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease","volume":"4","author":"Capodanno","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2018.09.057_bib70","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1161\/CIRCULATIONAHA.116.023952","article-title":"A\u00a0Critical Appraisal of Aspirin in Secondary Prevention","volume":"134","author":"Gargiulo","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.057_bib71","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41569-018-0049-1","article-title":"Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention","volume":"15","author":"Capodanno","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib72","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.057_bib73","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1161\/CIRCULATIONAHA.116.024823","article-title":"Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: clinical perspective","volume":"134","author":"Motovska","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.057_bib74","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12265-013-9527-3","volume":"7","author":"Schulz","year":"2014","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.jacc.2018.09.057_bib75","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamacardio.2018.0612","article-title":"Ticagrelor vs clopidogrel after fibrinolytic therapy in patients with st-elevation myocardial infarction: a randomized clinical trial","volume":"3","author":"Berwanger","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib76","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.09.057_bib77","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.057_bib78","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jacc.2018.02.029","article-title":"Pharmacogenomic approach to selecting antiplatelet therapy in acute coronary syndromes: PHARMCLO trial","volume":"71","author":"Notarangelo","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib79","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.jacc.2018.03.021","article-title":"Pharmacogenomic testing to select antiplatelet therapy","volume":"71","author":"Price","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib80","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/17512433.2017.1353909","article-title":"Role of genetic testing in patients undergoing percutaneous coronary intervention","volume":"11","author":"Moon","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jacc.2018.09.057_bib81","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","article-title":"Efficacy and safety of dual antiplatelet therapy after complex PCI","volume":"68","author":"Giustino","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib82","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.057_bib83","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","article-title":"Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates","volume":"65","author":"Valgimigli","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.057_bib84","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jcin.2015.11.015","article-title":"Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention?","volume":"9","author":"Ariotti","year":"2016","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2018.09.057_bib85","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free Drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.057_bib86","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","article-title":"Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial","volume":"391","author":"Varenne","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.057_bib87","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(17)30591-3","article-title":"Tailoring duration of DAPT with risk scores","volume":"389","author":"Capodanno","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.09.057_bib88","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ahj.2018.03.001","volume":"200","author":"Lopes","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2018.09.057_bib89","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ahj.2017.10.009","article-title":"Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial\u00a0fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial","volume":"196","author":"Vranckx","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2018.09.057_bib90","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jcin.2017.10.051","article-title":"A\u00a0multidisciplinary approach on the perioperative antithrombotic management of patients with coronary stents undergoing surgery","volume":"11","author":"Rossini","year":"2018","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.jacc.2018.09.057_bib91","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.acvd.2017.12.004","volume":"111","author":"Godier","year":"2018","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2018.09.057_bib92","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.recesp.2018.01.001","article-title":"Manejo perioperatorio y periprocedimiento del tratamiento antitromb\u00f3tico: documento de consenso de SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT y AEU","volume":"71","author":"Vivas","year":"2018","journal-title":"Rev Espa\u00f1ola Cardiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109718387369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109718387369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:18:19Z","timestamp":1760015899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109718387369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":90,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0735109718387369"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2018.09.057","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ACC\/AHA Versus ESC Guidelines on Dual\u00a0Antiplatelet Therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2018.09.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}